Spruce Street Capital
Spruce Street Capital reported 30 stocks worth $510M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are KNSA (11.5%), RLAY (10.9%) and LBRX (8.8%). Compared with Q1 2026, the fund opened new positions in IFRX, RACC and ZLAB, added to KNSA, RLMD and ANRO, trimmed DNTH and sold out of MAZE.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 3 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  KNSA Kiniksa Pharmaceuticals Intl | $58.7M | 11.5% | 918K | +157K (+21%) | 3 of 3 | |
| 2 |  RLAY Relay Therapeutics Inc | $55.8M | 10.9% | 3M | No change | 3 of 3 | |
| 3 |  LBRX LB Pharmaceuticals Inc | $44.7M | 8.8% | 1.4M | No change | 3 of 3 | |
| 4 |  RLMD Relmada Therapeutics Inc | $44.2M | 8.7% | 6.4M | +129K (+2%) | 3 of 3 | |
| 5 |  ANRO Alto Neuroscience Inc | $35.7M | 7.0% | 1.4M | +28K (+2%) | 3 of 3 | |
| 6 |  DNTH Dianthus Therapeutics Inc | $34.6M | 6.8% | 355K | −18K (−5%) | 3 of 3 | |
| 7 |  ALKS Alkermes PLC | $28.5M | 5.6% | 544K | +226K (+71%) | 2 of 3 | |
| 8 |  SVRA Savara Inc | $21.3M | 4.2% | 3.5M | +69K (+2%) | 3 of 3 | |
| 9 |  PCVX Vaxcyte Inc | $17.8M | 3.5% | 306K | +60K (+25%) | 3 of 3 | |
| 10 |  ELVN Enliven Therapeutics Inc | $16.7M | 3.3% | 329K | No change | 3 of 3 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CENTESSA PHARMACEUTICALS PLC | $19.5M | 490K |
KALVISTA PHARMACEUTICALS INC | $18.1M | 898K |
 MAZE Maze Therapeutics Inc | $6M | 200K |
Reported value
last 3 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 13, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Spruce Street Capital 13F FAQ
What does Spruce Street Capital own?
Spruce Street Capital reported 30 stocks worth $510M in its 13F filing for Q2 2026, filed Aug 13, 2026. Its largest holdings are KNSA (11.5%), RLAY (10.9%) and LBRX (8.8%). The table above lists every position in the filing (the top 10 without an account).
What did Spruce Street Capital buy and sell in Q2 2026?
Compared with Q1 2026: 5 new positions, 8 added to, 1 trimmed and 3 sold out. New positions include IFRX, RACC and ZLAB. It sold all of MAZE.
When will Spruce Street Capital file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Spruce Street Capital's portfolio worth?
The Q2 2026 filing reports $510M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.